Jan 12, 2026 09:00AM
Sep 17, 2025 08:00AM
Sep 17, 2025 08:00AM
Aug 21, 2025 07:00AM
Aug 21, 2025 07:00AM
Aug 5, 2025 08:00AM
Jul 31, 2025 08:32AM InspireMD raises $58 million through equity placement and warrant exercise
Jul 31, 2025 08:30AM
Jul 9, 2025 07:01AM
Jul 9, 2025 07:00AM
Jun 24, 2025 04:06PM
Jun 24, 2025 04:05PM
Jun 13, 2025 09:00AM
Jun 13, 2025 09:00AM InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
May 12, 2025 08:00AM
May 9, 2025 07:00AM
Mar 12, 2025 07:00AM
Feb 13, 2025 07:00AM
Dec 12, 2024 07:00AM
Dec 12, 2024 07:00AM
Dec 9, 2024 07:00AM InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Nov 12, 2024 07:00AM
Oct 15, 2024 07:00AM
Oct 7, 2024 07:04AM
Oct 7, 2024 07:00AM
Sep 17, 2024 07:17AM
Sep 16, 2024 07:07AM
Sep 16, 2024 07:00AM InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
Aug 6, 2024 08:09AM
Aug 5, 2024 07:00AM
Jul 1, 2024 07:00AM
May 28, 2024 08:53AM
May 14, 2024 07:00AM
Jan 31, 2024 07:01AM
Jan 31, 2024 07:00AM InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Dec 20, 2023 07:00AM
Dec 20, 2023 07:00AM
Nov 27, 2023 07:03AM
Nov 27, 2023 07:00AM
Nov 1, 2023 02:20PM
Nov 1, 2023 02:19PM
Oct 12, 2023 07:00AM InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
Aug 8, 2023 07:00AM
Jun 26, 2023 08:00AM
May 16, 2023 07:00AM
May 15, 2023 08:01AM
May 15, 2023 08:00AM
May 1, 2023 08:00AM
Mar 30, 2023 07:00AM InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Feb 14, 2023 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All